<DOC>
	<DOCNO>NCT02227316</DOCNO>
	<brief_summary>The uterine fibroid embolization ( UFE ) procedure treatment option abnormal heavy menstrual bleeding and/or bulk symptom associate uterine fibroid adenomyosis . Post UFE procedural pain nausea expect event . These symptom treat current standard care medication , include opiate . Intra procedure pain medication include midazolam , fentanyl hydromorphone . Some center include nonsteroidal anti-inflammatory medication ( NSAIDS ) , include oral ibuprofen IV ketorolac . Post procedural pain control center hydromorphone patient-controlled analgesia ( PCA ) infusion pump , well NSAID regimen . Intra procedure post procedure nausea control medication include transcutaneous scopolamine patch IV anti-nausea medication ondansetron prochlorperazine . This study conduct compare two new medication pain , IV ibuprofen IV acetaminophen , administer 24 hour follow UFE . The primary safety objective non-inferiority meet primary efficacy objective superiority , decrease pain nausea , access compare current standard care regimens . This 4 arm , double blind , randomize , control study . All patient receive standard care baseline pain medication , include IV midazolam , fentanyl hydromorphone intra procedure , follow hydromorphone PCA infusion pump post procedure . The 4 arm include : [ Arm 1 ] IV ibuprofen/IV placebo , [ Arm 2 ] IV acetaminophen/IV placebo , [ Arm 3 ] IV ibuprofen/IV acetaminophen , [ arm 4 ] IV placebo/IV placebo . These medication give procedure extend 24 hour stay . Arm 4 ( IV placebo/IV placebo ) would replicate current standard care , therefore include IV push ( IVP ) ketorolac , would give end procedure continue every 6 hour 24 hour stay . An IVP saline give control every 6 hour 24 hour stay arm 1 , 2 3 . Pain nausea measure interval prior procedure , throughout stay 2 week post procedure .</brief_summary>
	<brief_title>Effectiveness IV Acetaminophen IV Ibuprofen Reducing Post Procedural Pain UFE Procedure</brief_title>
	<detailed_description>A prospective , double blind , randomize control trial evaluate effect two new IV medication , IV ibuprofen IV acetaminophen , standard care pain anti-emetic management Uterine Fibroid Embolization patient . 1 . Four arm , double blind , randomize control study : patient receive standard care baseline pain medication , include IV midazolam , fentanyl hydromorphone procedure , follow hydromorphone PCA infusion pump recovery . The four arm include IV ibuprofen/IV placebo , IV acetaminophen/IV placebo , IV ibuprofen/IV acetaminophen , control arm ( IV placebo/IV placebo ) . The amount normal saline substitute experimental treatment patient receives placebo . These medication give procedure extend 24 hour recovery period . The medication give blind patient , administrator , surveyor . 2 . The placebo/placebo arm would replicate current standard care , therefore include IV push ( IVP ) ketorolac , would give end procedure continue 24 hour q6hour dose . An IVP saline would give control 24 hour q6hour dose three arm . 3 . Dosage medication standardize base formulary indication : IV Ketorolac 30 mg/dose IVP , acetaminophen 1 gram/dose IV piggy back 15 minute every 6 hour , ibuprofen 800 mg/dose IV piggy back 30 minute every 6 hour . 4 . Variables measure : pain ( VAS score 0 hour , 6 hour , discharge 2 week post procedure ) , opioid requirement , nausea ( VAS score 0 hour , 6 hour , discharge 2 week post procedure ) , anti-emetic medication requirement . Weighted sum pain intensity difference , pain intensity measure VAS 24 hour ( SPID24 ) use primary outcome . Satisfaction score measure 24 hour use validated APS-POQ-R questionnaire ( 6 ) . 5 . Other variable record : Age , height , weight , history postoperative nausea vomit motion sickness , diagnosis , uterine volume , dominant fibroid size , artery embolized , presence prominent ovarian artery , volume particle use , fluoroscopy time procedure . 6 . Technical parameter , would remain constant , include : pre procedure 6 month follow MRI contrast gadolinium standard care , embolization use 500-700 micron Embospheres ( limited use 700-900 micron Embospheres ) , IV hydration 0.9 % normal saline , antibiotic ( IV ciprofloxacin 400 mg every 12 hour , IV metronidazole 500 mg every six hour ) , urinary catheter placement , low extremity compression device , early ambulation . 7 . In interim analysis , investigator 40 subject total unequal randomization ratio 1:1:4:4 . Additional subject enrol total 35 subject per arm final analysis ( sum total N=140 )</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Adenomyosis</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1 . Patients consider UFE include bleed and/or bulk symptom . 2 . Women ethnicities 3 . Ages 2160 1 . Patients current malignancy receive treatment 2 . Women pregnant 3 . Cognitive impairment 4 . Clinically significant kidney disease 5 . Clinically significant liver disease 6 . Any recent history gastrointestinal bleed ulcer 7 . Weight le 50 kg ( medication dosing requirement change 50 kg ) 8 . Women body mass index ( BMI ) equal 50 ( comorbidities ) 9 . Known allergy hypersensitivity NSAID acetaminophen 10 . Administration acetaminophen , NSAID , narcotic analgesic le 6 hour prior UFE procedure 11 . Any chronic use pain medication include acetaminophen , NSAID , narcotic analgesic 12 . Patients choose consent participate study</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Uterine Fibroid Embolization</keyword>
	<keyword>Pain</keyword>
	<keyword>UFE</keyword>
	<keyword>Fibroids</keyword>
	<keyword>Adenomyosis</keyword>
	<keyword>Bleeding</keyword>
	<keyword>IV Acetaminophen</keyword>
	<keyword>IV Ibuprofen</keyword>
	<keyword>Menorrhagia</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Patient Satisfaction</keyword>
</DOC>